ANIP — ANI Pharmaceuticals Income Statement
0.000.00%
HealthcareAdventurousMid CapNeutral
- $658.33m
- $921.47m
- $316.39m
- 74
- 44
- 92
- 80
Annual income statement for ANI Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 202 | 207 | 208 | 216 | 316 |
Cost of Revenue | |||||
Gross Profit | 129 | 143 | 121 | 116 | 178 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 166 | 190 | 224 | 256 | 352 |
Operating Profit | 35.4 | 16.4 | -16 | -39.8 | -35.3 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 20.1 | 3.16 | -26 | -56.1 | -62.7 |
Provision for Income Taxes | |||||
Net Income After Taxes | 15.5 | 6.09 | -22.5 | -42.6 | -47.9 |
Net Income Before Extraordinary Items | |||||
Net Income | 15.5 | 6.09 | -22.5 | -42.6 | -47.9 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 15.3 | 6 | -22.5 | -42.8 | -49.5 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 1.3 | 0.864 | -1.25 | -2.78 | -2.81 |